Vocimagene amiretrorepvec-flucytosine gene therapy - Tocagen

Drug Profile

Vocimagene amiretrorepvec-flucytosine gene therapy - Tocagen

Alternative Names: Cytosine deaminase gene therapy-flucytosine; Flucytosine prodrug activating therapy - Tocagen; Toca 511 & Toca FC; Toca 511 + 5-FC; Toca-511 + Toca-FC; Vocimagene amiretrorepvec + 5-fluorocytosine; Vocimagene amiretrorepvec + flucytosine

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tocagen
  • Class Antineoplastics; Cytosine deaminase-flucytosine-gene-therapies; Pyrimidinones; Small molecules
  • Mechanism of Action DNA synthesis inhibitors; Gene transference; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Anaplastic astrocytoma; Glioblastoma
  • Phase I Glioma; Solid tumours
  • Preclinical Breast cancer

Most Recent Events

  • 16 Nov 2017 Phase I development is ongoing in Glioma (Late-stage disease) in USA (Intratumoural, Injection), in Glioma (Recurrent) in USA (PO, Controlled release) and USA (IV).
  • 09 Nov 2017 Updated pharmacodynamics data from preclinical and Phase I studies in Glioma released by Tocagen
  • 27 Oct 2017 Long-term efficacy data from a phase I trial in Glioblastoma released by Tocagen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top